butyric acid ba  (MedChemExpress)

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: Chemical structure of V9302.

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: Cytotoxic and antiproliferative effects of V9302, doxorubicin, and cisplatin on various breast cancer cell lines.

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: Synergistic interactions of V9302 with doxorubicin and cisplatin in breast cancer cell lines. Ratio *: the applied combination and the concentration of V9302:DOX or V9302:CIS combination.

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques: Concentration Assay

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: Interaction of V9302 and doxorubicin in the KCR breast cancer cell line.

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: V9302 causes changes in the cell cycle distribution in MCF-7 cells. The figure represents the percentages of the different cell cycle phases after the 24 and 48 h treatment with V9302. Data presented are mean ± SEM, *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively, compared to control samples ( A ). Selected histograms exemplify the cell cycle disturbances caused by V9302 at different concentrations after 24 h ( B , C ) and 48 h ( D , E ).

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques: Control

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: V9302 effects on the cell cycle distribution in Pgp-overexpressing KCR cells. Bar charts represent the percentages of the different cell cycle phases after the 24 and 48 h treatment with V9302. Data presented are mean ± SEM, *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively, compared to control samples ( A ). Selected histograms exemplify the cell cycle disturbances caused by V9302 at different concentrations after 24 h ( B – D ) and 48 h ( E – G ).

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques: Control

Journal: Pharmaceutics

Article Title: Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

doi: 10.3390/pharmaceutics16070877

Figure Lengend Snippet: ( A ): Rhodamine 123 accumulation in Pgp-overexpressing mouse T-lymphoma cells in the presence of V9302 at 2, 10, and 20 µM ( A ). Tariquidar was used at 0.2 µM as a positive control. PAR cells represent 100% rhodamine 123 accumulation. ( B ): Pgp ATPase inhibition: V9302 was applied at 20 µM. ∆RLU TC > ∆RLU basal : the tested compound (TC) is stimulator of Pgp ATPase activity; ∆RLU TC = ∆RLUbasal: the tested compound has no effect on Pgp ATPase activity; ∆RLU TC < ∆RLU basal : the tested compound is an inhibitor of Pgp ATPase activity, black line represents the basal Pgp ATPase activity, **** indicates p < 0.0001.

Article Snippet: The effect of V9302 ((2S)-2-amino-4-[bis[[2-[(3-methylphenyl)methoxy]phenyl]methyl]amino]butanoic acid; MedChemExpress, Monmouth Junction, NJ, USA) ( ) was investigated on several cell lines: breast cancer cell line MCF-7 (ATCC ® HTB-22) (purchased from LGC Promochem (Teddington, Middlesex, UK)), and its doxorubicin-resistant subline KCR; HTB-26TM breast adenocarcinoma (ATCC ® MDA-MB-231); and T-47D (ATCC ® HTB-133TM) ductal carcinoma of the breast; L5178Y mouse T-lymphoma cells (ECACC catalog no. 87111908, US FDA, Silver Spring, MD, USA) were transfected with the pHa MDR1/A retrovirus, as previously reported [ ].

Techniques: Positive Control, Inhibition, Activity Assay